Similar companies
Income Statement (USD)
| Q3 '24 | QoQ | |
|---|---|---|
| Revenue | 1.05B | 2.9% |
| Gross Profit | 571M | 7.6% |
| Cost of Revenue | 483M | 2.1% |
| Operating expense | 683M | 4.4% |
| Net Income | 215M | 27.6% |
| EBITDA | 418M | 17.8% |
Balance Sheet (USD)
| Q3 '24 | QoQ | |
|---|---|---|
| Total Assets | 12.3B | 7.9% |
| Total Liabilities | 8.08B | 6.4% |
| Total Equity | 4.17B | 10.9% |
| Shares Outstanding | 61M | 2.3% |
Cash Flow (USD)
| Q3 '24 | QoQ | |
|---|---|---|
| Cash from operations | 399M | 20.3% |
| Cash from investing | 214M | 183.3% |
| Cash from financing | 246M | 253% |
EPS
Financial Highlights for Jazz Pharmaceuticals in Q3 '24
Jazz Pharmaceuticals reported a revenue of 1.05B, which is a 2.9% change from the previous quarter. An increase in revenue typically indicates growing demand for the company's products or services. This positive change in revenue is a good sign, suggesting that the company's sales are moving in the right direction.
Gross Profit stood at 571M, marking a 7.6% change since the last quarter. Gross profit showcases the efficiency in production and sales processes.
Cost of Revenue was 483M, a -2.1% difference from the previous quarter. A rising cost of revenue may suggest increased production or sales costs, which can impact margins. However, if accompanied by a proportionate rise in revenue, it could indicate scaling operations.
Operating Expenses for this period were 683M, showing a -4.4% change from the last quarter. Operating expenses cover the costs of running daily business operations. A significant increase might indicate inefficiencies or investments in growth, while a decrease could suggest cost-saving measures or potential underinvestment in key areas.
Net Income for the quarter was 215M, showing a 27.6% change from the prior quarter. Net income provides a clear picture of the company's profitability after all expenses. An increase suggests the company is becoming more profitable, while a decrease may raise concerns about the company's financial health, unless there are specific one-time costs or investments.
The company's EBITDA for the quarter was 418M, showing a 17.8% change from the previous period. EBITDA gives insight into the company's operational profitability, excluding non-operating expenses like interest and taxes. A rising EBITDA indicates strong operational performance, while a declining EBITDA may signal operational challenges or increased costs.
It was a positive quarter for Jazz Pharmaceuticals with growth in revenue, gross profit, and net income.
